RecruitingNot ApplicableNCT06689839

Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR

A Prospective, Randomized, Multicenter, Single-blind Trial to Assess the Safety and Effectiveness of the Encompass F2 Cerebral Protection System Vs. Standard of Care (Unprotected or Sentinel® Cerebral Protection System) During Transfemoral Transcatheter Aortic Valve Replacement


Sponsor

EnCompass Technologies, Inc.

Enrollment

500 participants

Start Date

Sep 9, 2025

Study Type

INTERVENTIONAL

Summary

The objective of this study is to compare the safety and effectiveness of the F2 Cerebral Protection System (CPS) to a standard of care control group in patients undergoing Transcatheter Aortic Valve Replacement (TF TAVR)


Eligibility

Min Age: 50 Years

Inclusion Criteria5

  • Age ≥ 50 years.
  • Patient meets the established criteria and indications for commercially available TAVR via transfemoral access and is scheduled to undergo TAVR per their treating physician.
  • Patient is willing and able to comply with protocol-specified follow-up evaluations.
  • Patient is able and willing to provide written informed consent.
  • Patient meets all criteria for use of control device (Sentinel device, per IFU).

Exclusion Criteria25

  • Patient requires an urgent or emergent TAVR procedure.
  • Any interventional cardiovascular procedure performed within 30 days prior to TAVR procedure or planned within 30 days post-TAVR procedure.
  • Diagnostic cardiac catheterization within 10 days prior to TAVR procedure.
  • Evidence of an acute myocardial infarction within 3 months prior to TAVR procedure.
  • Prior prosthetic heart valve in any position.
  • Known intracardiac thrombus.
  • Active infection or endocarditis.
  • Patient is contraindicated for anti-platelet and/or anticoagulant therapy.
  • Patient refuses blood transfusion.
  • Renal insufficiency (creatinine > 2.5 mg/dL or GFR < 30) and/or renal replacement therapy at the time of screening.
  • Patients with hepatic failure (Child-Pugh class C).
  • Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) < 30%.
  • Females who are pregnant or nursing or plan to become pregnant during their participation in the study.
  • Modified Rankin Scale (mRS) ≥ 2 at screening.
  • Cerebrovascular event including TIA within 6 months of the procedure.
  • Patient has active major psychiatric disease, known mental or physical illness or known history of substance abuse that may cause non-compliance with the protocol or confound the data interpretation.
  • Patient has severe visual, auditory, or learning impairment.
  • Patient has neurodegenerative or other progressive neurological disease or history of significant head trauma followed by persistent neurologic defaults or known structural brain abnormalities.
  • Contraindications to MRI (participants with MR unsafe implants including implantable temporary or permanent pacemaker or defibrillator, metal implants in field of view, metallic fragments, clips, or devices in the brain or eye before TAVR procedure).
  • High risk of complete AV block after TAVR, with the need of permanent pacemaker.
  • Claustrophobia precluding MRI scanning.
  • Severe peripheral arterial, abdominal aortic, or thoracic aortic disease that precludes delivery sheath, vascular access or filter deployment.
  • Presence of cardiovascular implant in aorta and/or peripheral access vessels.
  • Access vessels with excessive tortuosity.
  • Aortic arch, which is heavily calcified, severely atheromatous, or severely tortuous.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEF2 Filter and Delivery System

Use of the F2 Filter and Delivery System in conjunction with a Transcatheter Aortic Valve Replacement (TAVR) procedure

PROCEDURETranscatheter Aortic Valve Replacement (TAVR)

Transcatheter Aortic Valve Replacement (TAVR) with commercially available Transcatheter Aortic Valve Replacement (TAVR) device


Locations(10)

NCH Baker Hospital-Naples Heart Institute

Naples, Florida, United States

St. Vincent Hospital

Indianappolis, Indiana, United States

Henry Ford Hospital

Detroit, Michigan, United States

St. Lukes Hospital Of Kansas City

Kansas City, Missouri, United States

Cumc/Nyph

New York, New York, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Ohio Health Research Institute (aka Riverside Methodist Hospital)

Columbus, Ohio, United States

University of Virginia Medical Center

Charlottesville, Virginia, United States

St Andrews War Memorial Hospital

Spring Hill, Queensland, Australia

Monash Health Public

Clayton, Victoria, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06689839